Sector News

U.S. approves GSK’s purchase of Novartis vaccine business: companies

November 27, 2014
Life sciences
(Reuters) – GlaxoSmithKline won U.S. antitrust approval to buy Novartis AG’s vaccine business, with the exception of influenza vaccines, the two companies said on Wednesday.
 
The deal is part of a three-way transaction unveiled in April, which includes Britain’s GSK buying the vaccines business of Novartis, the Swiss company purchasing GSK’s cancer drugs, and the two groups tying up in consumer healthcare.
 
The U.S. Federal Trade Commission had previously announced on Wednesday that it approved the consumer health care joint venture on the condition that Novartis sell its Habitrol nicotine patch.
 
Novartis and Glaxo, which has Nicoderm CQ, are two of only three companies that sell nicotine patches to U.S. retailers, the FTC said.
 
(Reporting by Diane Bartz; Editing by Diane Craft)

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]